RareResearch.AI
← Back to atlas

R457S

Category 4 — Stable Fold, Function DisruptedConflictingTransmembrane · predictedEditorial
ArginineSerine at position 457 · Connecting loop · WFS1 (Wolframin)

Arginine → Serine at position 457 in connecting loop. ClinVar Conflicting including monogenic diabetes + spastic. AlphaMissense 0.515 (borderline), ΔΔG -0.82.

Interactive 3D Structure

Wild-type reference
Wild-type R457 — hydrogen bond to P453
Fullscreen ↗
DynaMut2 mutant · R457S
Mutant S457 — hydrogen bond contact to Y454 lost
Fullscreen ↗

Bond changes · DynaMut2 interaction analysis

1 lost2 gained8 preserved
Interaction typeWild-type partnerMutant partnerStatus
Hydrogen bondP453P453Preserved
Hydrogen bondY454Y454Preserved
Hydrogen bondA460A460Preserved
Hydrogen bondT461T461Preserved
Polar contactP453P453Preserved
Polar contactY454Y454Preserved
Polar contactT455Gained
Polar contactA460A460Preserved
Polar contactT461T461Preserved
Polar contactL514Gained
HydrophobicL514Lost

Lost / gained / preserved interatomic contacts at the variant residue, from the DynaMut2 (Arpeggio) interaction analysis of the wild-type and energy-minimized mutant structures.

Computational Predictions

DynaMut2 ΔΔG
-0.82kcal/mol
Destabilising — mild
AlphaMissense
0.515
Amb
AlphaFold pLDDT
88
model confidence
Schema
Cat 4
Category 4 — Stable Fold, Function Disrupted
ΔΔG confidence: Reduced confidence · Transmembrane
  • transmembrane position; predictor benchmarked on soluble proteins

This variant sits in the transmembrane band. The stability value was computed with a predictor benchmarked on water-soluble proteins. Published benchmarks of ddG predictors on membrane proteins report correlation below 0.4. Treat the magnitude as unreliable and the sign as weak evidence only.

Do not rank this value against a variant from a different region on ΔΔG alone.

Clinical Evidence

ClinVar classificationConflicting classifications of pathogenicity
Review statuscriteria provided, conflicting classifications
Associated conditionsWFS1-related disorder; Monogenic diabetes; Spastic ataxia
InheritanceMonogenic diabetes + WFS1 spectrum.
Population frequency (gnomAD v4)Low frequency · AF 0.047%
cDNA changec.1371G>T
ClinVar accessionVCV000215389
Last evaluated2025/11/18 00:00

Observed in the general population.

Classified for1★ unverified submission

ClinVar classifies this variant as Conflicting classifications of pathogenicity for WFS1-related spectrum (unresolved mode) (dominant or recessive); WFS1-related diabetes (autosomal dominant); Ataxia / spastic ataxia (inheritance not specified); Wolfram syndrome (classic) (autosomal recessive, OMIM 222300); Cataract 41 (autosomal dominant, OMIM 116400); Nonsyndromic hearing loss (DFNA6/14/38) (autosomal dominant, OMIM 600965); Wolfram-like syndrome (autosomal dominant, OMIM 614296); Hearing loss, inheritance unstated (inheritance not specified). ClinVar records this under a WFS1-spectrum label that spans both disease families — recessive Wolfram syndrome (biallelic) and the dominant WFS1-related disorders. The label does not resolve which applies, and it is not a severity statement.

  • WFS1-related spectrum (unresolved mode)dominant or recessivesubmitted as: WFS1-related disorder; WFS1-Related Spectrum Disorders
  • WFS1-related diabetesautosomal dominantsubmitted as: Monogenic diabetes; Type 2 diabetes mellitus
  • Ataxia / spastic ataxiainheritance not specifiedsubmitted as: Spastic ataxia
  • Wolfram syndrome (classic)autosomal recessive · OMIM 222300submitted as: Wolfram syndrome 1
  • Cataract 41autosomal dominant · OMIM 116400submitted as: Cataract 41
  • Nonsyndromic hearing loss (DFNA6/14/38)autosomal dominant · OMIM 600965submitted as: Autosomal dominant nonsyndromic hearing loss 6; Autosomal dominant nonsyndromic hearing loss 6
  • Wolfram-like syndromeautosomal dominant · OMIM 614296submitted as: Wolfram-like syndrome
  • Hearing loss, inheritance unstatedinheritance not specifiedsubmitted as: Hearing impairment
  • Submitters conflict on this classification (1★). Treat the conditions above as submitted, not as documented phenotypes.
  • Phenotype scope is interpretation of submitted records. The computed values on this card (AlphaMissense, DynaMut2 ΔΔG, pLDDT) are measurements of the model, not of a patient.
  • Presentation cannot be generalised from neighbouring variants: one nucleotide over can present very differently. Structural similarity supports a mechanistic hypothesis, never a phenotype claim.

Review status: 1★ conflicting classifications. ClinVar "conditions" is the union of all submissions; 0–1★ entries are submitted conditions, not documented phenotypes.

Population frequency
Global (all ancestries)
AF 0.047% · 762 / 1,612,410 alleles
Homozygotes
2
Highest-frequency population
European (non-Finnish) · AF 0.061%

Highest in European (non-Finnish): AF 0.061% (720 of 1,179,846 alleles), in line with the global figure.

2 homozygotes reported in gnomAD v4 (2 European (non-Finnish)). gnomAD excludes individuals with severe pediatric disease, so homozygotes in this dataset argue against a fully penetrant severe recessive phenotype and belong in the clinical picture. This is interpretive signal, not a classification.

Ancestry groupAllele freq.AC / ANHom.Carrier est.
European (non-Finnish)0.061%720 / 1,179,8462~1 in 820
Remaining individuals0.037%23 / 62,4840~1 in 1360
African / African American0.015%11 / 75,0380~1 in 3410
Admixed American0.0050%3 / 60,0200~1 in 10000
Ashkenazi Jewish · under-sampled0.0034%1 / 29,6080
South Asian0.0033%3 / 91,0760~1 in 15180
Finnish · under-sampled0.0016%1 / 62,5060

Source: gnomAD r4, retrieved 2026-08-21. Values are allele frequencies. The carrier estimate is derived from the allele frequency (Hardy-Weinberg, ~2·AF) and is an approximation, not a published figure — where a published carrier frequency exists it outranks this column and is cited on the card.

Structural Context

Position 457 in connecting loop. Neighbors: ALA458 (2.5 Å), ARG456 (2.5 Å — adjacent existing arginine!), TYR454 (3.7 Å), PRO453 (4.1 Å).

Replacing R457 with serine eliminates one of two adjacent arginines (R456 + R457). The local positively-charged surface character is reduced. ΔΔG 0.82 + AM 0.515 borderline + monogenic diabetes confirm severe consequence.

Amino-acid chemistry
Arginine (R) → Serine (S) — long positively-charged amine replaced by small polar hydroxyl. Loss of charge + side-chain length.
Position in the protein
Connecting loop · position 457 (pLDDT 88).

Druggability Assessment

Category 3/4 — Most Druggable. |ΔΔG| = 0.82. AlphaMissense 0.515 borderline + multi-phenotype confirm severe consequence.

Mechanism: loss of R457 charge from R456-R457 cluster. Therapeutic: site-directed at the loop's charged surface.

Why this matters

R457S continues the charge-loss class in connecting loops.
Therapeutic Strategy Handoff · prediction

Feed this card to Wolfram Intelligence

Download the R457S PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.

Download R457S PDF card ↓Strategies are AI-generated predictions, not validated therapeutics.

UniProt Domain Annotation

Chain1890 · Wolframin
Natural variant457457 · in WFS1; dbSNP:rs113446173